Biological sex differences in Alzheimer's preclinical research: A call to action.

Autor: Waters A; Virginia Department of Health, Office of Epidemiology, Division of Clinical Epidemiology The George Washington University Washington, D.C. USA., Laitner MH; Director of Public Policy & Government Affairs The Society for Women's Health Research Washington, D.C. USA.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia (New York, N. Y.) [Alzheimers Dement (N Y)] 2021 Feb 14; Vol. 7 (1), pp. e12111. Date of Electronic Publication: 2021 Feb 14 (Print Publication: 2021).
DOI: 10.1002/trc2.12111
Abstrakt: Introduction: For decades, researchers have largely ignored sex as a biological variable (SABV) within preclinical studies. Recent literature indicates scientists are increasingly including male and female subjects in studies, but fewer studies assess for sex differences in study outcome. This is particularly concerning within the field of Alzheimer's disease (AD), as disease burden is higher among women and evidence suggests sex differences exist in etiology and disease course.
Methods: We conducted an informal review of preclinical AD research studies.
Results: Results confirmed that only about one-third of ≈150 recent studies included both male and female mice, and <15 of nearly 150 studies examined SABV as an outcome of interest.
Discussion: Previous research supports the idea that better integration of SABV could open new doors in treatment research. We provide examples of best practices and discuss the need for Alzheimer's researchers to account for SABV within preclinical studies.
Competing Interests: The authors declare there are no conflicts of interest.
(© 2021 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.)
Databáze: MEDLINE
Externí odkaz: